Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2RL1 | P55085 | 1/20 | 0.60 |
| ▸ | FASN | P49327 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MKNK1 | Q9BUB5 | 6/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 6/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.42 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.42 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | ACACA | Q13085 | 1/20 | 0.42 |
| ▸ | EIF4E | P06730 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15071125 | 0.89 | PLA2G7 (0.54) | F2RL1TSHRMKNK1MKNK2NPSR1 | |
| SCHEMBL15071122 | 0.86 | F2RL1 (0.67) | F2RL1FASNTSHRKMT2AMKNK1 | |
| SCHEMBL31503 | 0.76 | ADORA2A (0.53) | TSHRKMT2AMKNK1MKNK2MEN1 | |
| SCHEMBL31519 | 0.75 | F2RL1 (1.00) | F2RL1FASNTSHRKMT2AMEN1 | |
| SCHEMBL31554 | 0.71 | MKNK1 (0.63) | MKNK1MKNK2ADORA2AEIF4E | |
| SCHEMBL15071118 | 0.71 | MKNK1 (0.53) | MKNK1MKNK2ADORA2AEIF4E | |
| SCHEMBL31533 | 0.70 | F2RL1 (0.82) | F2RL1FASNKMT2AACACBACACA | |
| SCHEMBL15071119 | 0.70 | MKNK1 (0.52) | KMT2AMKNK1MKNK2ADORA2A | |
| SCHEMBL15071123 | 0.70 | HPGD (0.56) | MKNK1MKNK2ADORA2A | |
| SCHEMBL31526 | 0.69 | F2RL1 (0.90) | F2RL1FASNTSHRKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2617721-A2 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | Neopharm Co., Ltd. (KR) | 2013-07-24 | — | — | EP | disclosed |
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | NEOPHARM CO.,LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165652-A1 | NOVEL HETEROCYCLIC COMPOUND, AND COMPOSITION FOR TREATING INFLAMMATORY DISEASES USING SAME | F2RL1, F2R, FPR2 | F2RL1 1/4885FASN 2594/4885TSHR 4593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.